Bluejay Diagnostics updates Symphony IL-6 regulatory strategy, expands trial to sepsis patients

Bluejay Diagnostics, Inc.

Trial widened from severe COVID-19 only to all hospitalized sepsis patients to speed enrollment while maintaining H1 2024 submission timeline.
Company to submit FDA pre-submission application for revised study design in Q2 2023.
New indication for risk stratification of hospitalized sepsis patients aligns with recent FDA feedback.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.